nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—vagus nerve—obesity	0.091	0.619	CbGeAlD
Fosaprepitant—TACR1—respiratory system—obesity	0.0163	0.111	CbGeAlD
Fosaprepitant—TACR1—adipose tissue—obesity	0.011	0.0747	CbGeAlD
Fosaprepitant—TACR1—digestive system—obesity	0.0103	0.0703	CbGeAlD
Fosaprepitant—TACR1—adrenal gland—obesity	0.00985	0.067	CbGeAlD
Fosaprepitant—TACR1—endocrine gland—obesity	0.00854	0.0581	CbGeAlD
Fosaprepitant—Malnutrition—Orlistat—obesity	0.000804	0.0016	CcSEcCtD
Fosaprepitant—Disorientation—Topiramate—obesity	0.000802	0.0016	CcSEcCtD
Fosaprepitant—Vomiting—Diethylpropion—obesity	0.000794	0.00158	CcSEcCtD
Fosaprepitant—Flatulence—Orlistat—obesity	0.000792	0.00158	CcSEcCtD
Fosaprepitant—Rash—Diethylpropion—obesity	0.000787	0.00157	CcSEcCtD
Fosaprepitant—Dysgeusia—Orlistat—obesity	0.000787	0.00157	CcSEcCtD
Fosaprepitant—Dermatitis—Diethylpropion—obesity	0.000787	0.00157	CcSEcCtD
Fosaprepitant—Dizziness—Cimetidine—obesity	0.000786	0.00157	CcSEcCtD
Fosaprepitant—Headache—Diethylpropion—obesity	0.000782	0.00156	CcSEcCtD
Fosaprepitant—Malnutrition—Sibutramine—obesity	0.000778	0.00155	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Bupropion—obesity	0.000775	0.00155	CcSEcCtD
Fosaprepitant—Muscle spasms—Orlistat—obesity	0.000773	0.00154	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Bupropion—obesity	0.000769	0.00153	CcSEcCtD
Fosaprepitant—Hot flush—Topiramate—obesity	0.000767	0.00153	CcSEcCtD
Fosaprepitant—Flatulence—Sibutramine—obesity	0.000767	0.00153	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Bupropion—obesity	0.000766	0.00153	CcSEcCtD
Fosaprepitant—Urethral disorder—Bupropion—obesity	0.000764	0.00152	CcSEcCtD
Fosaprepitant—Dysgeusia—Sibutramine—obesity	0.000762	0.00152	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Topiramate—obesity	0.00076	0.00152	CcSEcCtD
Fosaprepitant—Vomiting—Cimetidine—obesity	0.000756	0.00151	CcSEcCtD
Fosaprepitant—Rash—Cimetidine—obesity	0.000749	0.00149	CcSEcCtD
Fosaprepitant—Dermatitis—Cimetidine—obesity	0.000749	0.00149	CcSEcCtD
Fosaprepitant—Muscle spasms—Sibutramine—obesity	0.000748	0.00149	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Orlistat—obesity	0.000746	0.00149	CcSEcCtD
Fosaprepitant—Headache—Cimetidine—obesity	0.000744	0.00148	CcSEcCtD
Fosaprepitant—Nausea—Diethylpropion—obesity	0.000742	0.00148	CcSEcCtD
Fosaprepitant—Erythema multiforme—Bupropion—obesity	0.000737	0.00147	CcSEcCtD
Fosaprepitant—Angioedema—Orlistat—obesity	0.000735	0.00146	CcSEcCtD
Fosaprepitant—Lethargy—Topiramate—obesity	0.000732	0.00146	CcSEcCtD
Fosaprepitant—Eye disorder—Bupropion—obesity	0.000728	0.00145	CcSEcCtD
Fosaprepitant—Tinnitus—Bupropion—obesity	0.000726	0.00145	CcSEcCtD
Fosaprepitant—Malaise—Orlistat—obesity	0.000725	0.00144	CcSEcCtD
Fosaprepitant—Cardiac disorder—Bupropion—obesity	0.000723	0.00144	CcSEcCtD
Fosaprepitant—Flushing—Bupropion—obesity	0.000723	0.00144	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Sibutramine—obesity	0.000722	0.00144	CcSEcCtD
Fosaprepitant—Hyponatraemia—Topiramate—obesity	0.00072	0.00144	CcSEcCtD
Fosaprepitant—Anaemia—Sibutramine—obesity	0.000719	0.00143	CcSEcCtD
Fosaprepitant—Osteoarthritis—Topiramate—obesity	0.000718	0.00143	CcSEcCtD
Fosaprepitant—Angioedema—Sibutramine—obesity	0.000711	0.00142	CcSEcCtD
Fosaprepitant—Palpitations—Orlistat—obesity	0.00071	0.00142	CcSEcCtD
Fosaprepitant—Angiopathy—Bupropion—obesity	0.000707	0.00141	CcSEcCtD
Fosaprepitant—Nausea—Cimetidine—obesity	0.000706	0.00141	CcSEcCtD
Fosaprepitant—Immune system disorder—Bupropion—obesity	0.000704	0.0014	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Bupropion—obesity	0.000702	0.0014	CcSEcCtD
Fosaprepitant—Malaise—Sibutramine—obesity	0.000702	0.0014	CcSEcCtD
Fosaprepitant—Cough—Orlistat—obesity	0.000701	0.0014	CcSEcCtD
Fosaprepitant—Syncope—Sibutramine—obesity	0.000698	0.00139	CcSEcCtD
Fosaprepitant—Palpitations—Sibutramine—obesity	0.000687	0.00137	CcSEcCtD
Fosaprepitant—Chest pain—Orlistat—obesity	0.000684	0.00136	CcSEcCtD
Fosaprepitant—Loss of consciousness—Sibutramine—obesity	0.000684	0.00136	CcSEcCtD
Fosaprepitant—Mental disorder—Bupropion—obesity	0.000683	0.00136	CcSEcCtD
Fosaprepitant—Anxiety—Orlistat—obesity	0.000682	0.00136	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.00068	0.00135	CcSEcCtD
Fosaprepitant—Cough—Sibutramine—obesity	0.000679	0.00135	CcSEcCtD
Fosaprepitant—Malnutrition—Bupropion—obesity	0.000678	0.00135	CcSEcCtD
Fosaprepitant—Discomfort—Orlistat—obesity	0.000676	0.00135	CcSEcCtD
Fosaprepitant—Hypertension—Sibutramine—obesity	0.000672	0.00134	CcSEcCtD
Fosaprepitant—Dry mouth—Orlistat—obesity	0.000669	0.00133	CcSEcCtD
Fosaprepitant—Flatulence—Bupropion—obesity	0.000668	0.00133	CcSEcCtD
Fosaprepitant—Dysgeusia—Bupropion—obesity	0.000664	0.00132	CcSEcCtD
Fosaprepitant—Chest pain—Sibutramine—obesity	0.000662	0.00132	CcSEcCtD
Fosaprepitant—Anxiety—Sibutramine—obesity	0.00066	0.00132	CcSEcCtD
Fosaprepitant—Oedema—Orlistat—obesity	0.000656	0.00131	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Orlistat—obesity	0.000656	0.00131	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Topiramate—obesity	0.000655	0.00131	CcSEcCtD
Fosaprepitant—Discomfort—Sibutramine—obesity	0.000654	0.0013	CcSEcCtD
Fosaprepitant—Hypokalaemia—Topiramate—obesity	0.000653	0.0013	CcSEcCtD
Fosaprepitant—Muscle spasms—Bupropion—obesity	0.000652	0.0013	CcSEcCtD
Fosaprepitant—Infection—Orlistat—obesity	0.000652	0.0013	CcSEcCtD
Fosaprepitant—Dry mouth—Sibutramine—obesity	0.000648	0.00129	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Topiramate—obesity	0.000646	0.00129	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Topiramate—obesity	0.000646	0.00129	CcSEcCtD
Fosaprepitant—Nervous system disorder—Orlistat—obesity	0.000643	0.00128	CcSEcCtD
Fosaprepitant—Skin disorder—Orlistat—obesity	0.000637	0.00127	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Sibutramine—obesity	0.000635	0.00127	CcSEcCtD
Fosaprepitant—Oedema—Sibutramine—obesity	0.000635	0.00127	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Orlistat—obesity	0.000634	0.00126	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Topiramate—obesity	0.000633	0.00126	CcSEcCtD
Fosaprepitant—Muscular weakness—Topiramate—obesity	0.000633	0.00126	CcSEcCtD
Fosaprepitant—Infection—Sibutramine—obesity	0.000631	0.00126	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Bupropion—obesity	0.000629	0.00125	CcSEcCtD
Fosaprepitant—Anaemia—Bupropion—obesity	0.000627	0.00125	CcSEcCtD
Fosaprepitant—Shock—Sibutramine—obesity	0.000625	0.00125	CcSEcCtD
Fosaprepitant—Abdominal distension—Topiramate—obesity	0.000624	0.00124	CcSEcCtD
Fosaprepitant—Angioedema—Bupropion—obesity	0.00062	0.00124	CcSEcCtD
Fosaprepitant—Skin disorder—Sibutramine—obesity	0.000617	0.00123	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Sibutramine—obesity	0.000614	0.00122	CcSEcCtD
Fosaprepitant—Malaise—Bupropion—obesity	0.000612	0.00122	CcSEcCtD
Fosaprepitant—Syncope—Bupropion—obesity	0.000608	0.00121	CcSEcCtD
Fosaprepitant—Palpitations—Bupropion—obesity	0.000599	0.00119	CcSEcCtD
Fosaprepitant—Loss of consciousness—Bupropion—obesity	0.000596	0.00119	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Topiramate—obesity	0.000595	0.00119	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—NPY2R—obesity	0.000594	0.00169	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—NPY1R—obesity	0.000594	0.00169	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MC3R—obesity	0.000594	0.00169	CbGpPWpGaD
Fosaprepitant—Insomnia—Orlistat—obesity	0.000593	0.00118	CcSEcCtD
Fosaprepitant—Hypotension—Sibutramine—obesity	0.000593	0.00118	CcSEcCtD
Fosaprepitant—Cough—Bupropion—obesity	0.000592	0.00118	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—HTR2C—obesity	0.000592	0.00168	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—DRD1—obesity	0.000592	0.00168	CbGpPWpGaD
Fosaprepitant—Hypertension—Bupropion—obesity	0.000586	0.00117	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PPY—obesity	0.000582	0.00166	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—obesity	0.000581	0.00165	CbGpPWpGaD
Fosaprepitant—Dysuria—Topiramate—obesity	0.00058	0.00116	CcSEcCtD
Fosaprepitant—Dyspepsia—Orlistat—obesity	0.000577	0.00115	CcSEcCtD
Fosaprepitant—Chest pain—Bupropion—obesity	0.000577	0.00115	CcSEcCtD
Fosaprepitant—Anxiety—Bupropion—obesity	0.000575	0.00115	CcSEcCtD
Fosaprepitant—Insomnia—Sibutramine—obesity	0.000574	0.00114	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000573	0.00114	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB1—obesity	0.000573	0.00163	CbGpPWpGaD
Fosaprepitant—Pollakiuria—Topiramate—obesity	0.000573	0.00114	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCH—obesity	0.000571	0.00163	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GIP—obesity	0.000571	0.00163	CbGpPWpGaD
Fosaprepitant—Discomfort—Bupropion—obesity	0.00057	0.00114	CcSEcCtD
Fosaprepitant—Decreased appetite—Orlistat—obesity	0.00057	0.00114	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—POMC—obesity	0.000568	0.00162	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Orlistat—obesity	0.000566	0.00113	CcSEcCtD
Fosaprepitant—Dyspnoea—Sibutramine—obesity	0.000566	0.00113	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Topiramate—obesity	0.000566	0.00113	CcSEcCtD
Fosaprepitant—Fatigue—Orlistat—obesity	0.000566	0.00113	CcSEcCtD
Fosaprepitant—Dry mouth—Bupropion—obesity	0.000565	0.00113	CcSEcCtD
Fosaprepitant—Somnolence—Sibutramine—obesity	0.000564	0.00113	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—obesity	0.000564	0.00161	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PMCH—obesity	0.000562	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NPY5R—obesity	0.000562	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HCRT—obesity	0.000562	0.0016	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NMU—obesity	0.000562	0.0016	CbGpPWpGaD
Fosaprepitant—Weight decreased—Topiramate—obesity	0.000561	0.00112	CcSEcCtD
Fosaprepitant—Pain—Orlistat—obesity	0.000561	0.00112	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GHRL—obesity	0.000561	0.0016	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Sibutramine—obesity	0.000559	0.00111	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—DRD4—obesity	0.000556	0.00158	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL2—obesity	0.000555	0.00158	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRLH—obesity	0.000555	0.00158	CbGpPWpGaD
Fosaprepitant—Oedema—Bupropion—obesity	0.000554	0.0011	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Bupropion—obesity	0.000554	0.0011	CcSEcCtD
Fosaprepitant—Infestation NOS—Topiramate—obesity	0.000553	0.0011	CcSEcCtD
Fosaprepitant—Infestation—Topiramate—obesity	0.000553	0.0011	CcSEcCtD
Fosaprepitant—Decreased appetite—Sibutramine—obesity	0.000552	0.0011	CcSEcCtD
Fosaprepitant—Infection—Bupropion—obesity	0.00055	0.0011	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Topiramate—obesity	0.000548	0.00109	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Sibutramine—obesity	0.000548	0.00109	CcSEcCtD
Fosaprepitant—Shock—Bupropion—obesity	0.000545	0.00109	CcSEcCtD
Fosaprepitant—Constipation—Sibutramine—obesity	0.000543	0.00108	CcSEcCtD
Fosaprepitant—Pain—Sibutramine—obesity	0.000543	0.00108	CcSEcCtD
Fosaprepitant—Nervous system disorder—Bupropion—obesity	0.000543	0.00108	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—obesity	0.000541	0.00154	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Orlistat—obesity	0.000541	0.00108	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—NPY1R—obesity	0.000539	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MC3R—obesity	0.000539	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NPY2R—obesity	0.000539	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MC4R—obesity	0.000539	0.00153	CbGpPWpGaD
Fosaprepitant—Stomatitis—Topiramate—obesity	0.000539	0.00107	CcSEcCtD
Fosaprepitant—Skin disorder—Bupropion—obesity	0.000538	0.00107	CcSEcCtD
Fosaprepitant—Urinary tract infection—Topiramate—obesity	0.000537	0.00107	CcSEcCtD
Fosaprepitant—Conjunctivitis—Topiramate—obesity	0.000537	0.00107	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Orlistat—obesity	0.000536	0.00107	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Bupropion—obesity	0.000535	0.00107	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CNR1—obesity	0.000531	0.00151	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PPY—obesity	0.000529	0.0015	CbGpPWpGaD
Fosaprepitant—Haematuria—Topiramate—obesity	0.000527	0.00105	CcSEcCtD
Fosaprepitant—Feeling abnormal—Sibutramine—obesity	0.000523	0.00104	CcSEcCtD
Fosaprepitant—Urticaria—Orlistat—obesity	0.000521	0.00104	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Sibutramine—obesity	0.000519	0.00103	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCH—obesity	0.000519	0.00148	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GIP—obesity	0.000519	0.00148	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Orlistat—obesity	0.000519	0.00103	CcSEcCtD
Fosaprepitant—Abdominal pain—Orlistat—obesity	0.000519	0.00103	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—DRD2—obesity	0.000518	0.00148	CbGpPWpGaD
Fosaprepitant—Hypotension—Bupropion—obesity	0.000517	0.00103	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GCG—obesity	0.000513	0.00146	CbGpPWpGaD
Fosaprepitant—Bradycardia—Topiramate—obesity	0.000505	0.00101	CcSEcCtD
Fosaprepitant—Urticaria—Sibutramine—obesity	0.000504	0.00101	CcSEcCtD
Fosaprepitant—Abdominal pain—Sibutramine—obesity	0.000502	0.001	CcSEcCtD
Fosaprepitant—Body temperature increased—Sibutramine—obesity	0.000502	0.001	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3R1—obesity	0.000501	0.00143	CbGpPWpGaD
Fosaprepitant—Insomnia—Bupropion—obesity	0.000501	0.000998	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Topiramate—obesity	0.000494	0.000984	CcSEcCtD
Fosaprepitant—Dyspnoea—Bupropion—obesity	0.000493	0.000984	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—obesity	0.000493	0.0014	CbGpPWpGaD
Fosaprepitant—Somnolence—Bupropion—obesity	0.000492	0.000981	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Topiramate—obesity	0.00049	0.000977	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Topiramate—obesity	0.000488	0.000972	CcSEcCtD
Fosaprepitant—Dyspepsia—Bupropion—obesity	0.000487	0.000971	CcSEcCtD
Fosaprepitant—Urethral disorder—Topiramate—obesity	0.000487	0.00097	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB3—obesity	0.000486	0.00138	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Orlistat—obesity	0.000483	0.000963	CcSEcCtD
Fosaprepitant—Decreased appetite—Bupropion—obesity	0.000481	0.000959	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—obesity	0.00048	0.00137	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—obesity	0.000479	0.00136	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Bupropion—obesity	0.000478	0.000953	CcSEcCtD
Fosaprepitant—Fatigue—Bupropion—obesity	0.000477	0.000951	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—obesity	0.000477	0.00136	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—C3—obesity	0.000476	0.00135	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GAL—obesity	0.000475	0.00135	CbGpPWpGaD
Fosaprepitant—Pain—Bupropion—obesity	0.000473	0.000943	CcSEcCtD
Fosaprepitant—Constipation—Bupropion—obesity	0.000473	0.000943	CcSEcCtD
Fosaprepitant—Asthenia—Orlistat—obesity	0.000471	0.000938	CcSEcCtD
Fosaprepitant—Erythema multiforme—Topiramate—obesity	0.000469	0.000935	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—C5AR1—obesity	0.000469	0.00134	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Sibutramine—obesity	0.000468	0.000932	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—obesity	0.000464	0.00132	CbGpPWpGaD
Fosaprepitant—Pruritus—Orlistat—obesity	0.000464	0.000925	CcSEcCtD
Fosaprepitant—Eye disorder—Topiramate—obesity	0.000464	0.000925	CcSEcCtD
Fosaprepitant—Tinnitus—Topiramate—obesity	0.000463	0.000922	CcSEcCtD
Fosaprepitant—Cardiac disorder—Topiramate—obesity	0.000461	0.000918	CcSEcCtD
Fosaprepitant—Flushing—Topiramate—obesity	0.000461	0.000918	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NMB—obesity	0.000459	0.00131	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHRH—obesity	0.000459	0.00131	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—obesity	0.000457	0.0013	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Bupropion—obesity	0.000456	0.000909	CcSEcCtD
Fosaprepitant—Asthenia—Sibutramine—obesity	0.000456	0.000908	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Bupropion—obesity	0.000453	0.000902	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—obesity	0.000452	0.00129	CbGpPWpGaD
Fosaprepitant—Angiopathy—Topiramate—obesity	0.00045	0.000898	CcSEcCtD
Fosaprepitant—Pruritus—Sibutramine—obesity	0.000449	0.000895	CcSEcCtD
Fosaprepitant—Diarrhoea—Orlistat—obesity	0.000449	0.000895	CcSEcCtD
Fosaprepitant—Immune system disorder—Topiramate—obesity	0.000448	0.000894	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—obesity	0.000448	0.00128	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—obesity	0.000447	0.00127	CbGpPWpGaD
Fosaprepitant—Mediastinal disorder—Topiramate—obesity	0.000447	0.000892	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—GNB3—obesity	0.000442	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB3—obesity	0.000441	0.00126	CbGpPWpGaD
Fosaprepitant—Urticaria—Bupropion—obesity	0.00044	0.000876	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FFAR4—obesity	0.000438	0.00125	CbGpPWpGaD
Fosaprepitant—Abdominal pain—Bupropion—obesity	0.000438	0.000872	CcSEcCtD
Fosaprepitant—Body temperature increased—Bupropion—obesity	0.000438	0.000872	CcSEcCtD
Fosaprepitant—Mental disorder—Topiramate—obesity	0.000435	0.000867	CcSEcCtD
Fosaprepitant—Diarrhoea—Sibutramine—obesity	0.000434	0.000866	CcSEcCtD
Fosaprepitant—Dizziness—Orlistat—obesity	0.000434	0.000865	CcSEcCtD
Fosaprepitant—Malnutrition—Topiramate—obesity	0.000432	0.000861	CcSEcCtD
Fosaprepitant—Erythema—Topiramate—obesity	0.000432	0.000861	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GAL—obesity	0.000431	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GNAS—obesity	0.000431	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCK—obesity	0.000429	0.00122	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—C5AR1—obesity	0.000426	0.00121	CbGpPWpGaD
Fosaprepitant—Flatulence—Topiramate—obesity	0.000426	0.000849	CcSEcCtD
Fosaprepitant—Dysgeusia—Topiramate—obesity	0.000423	0.000843	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MCHR1—obesity	0.00042	0.0012	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BRS3—obesity	0.00042	0.0012	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHSR—obesity	0.00042	0.0012	CbGpPWpGaD
Fosaprepitant—Dizziness—Sibutramine—obesity	0.00042	0.000837	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GLP1R—obesity	0.000418	0.00119	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—F2—obesity	0.000418	0.00119	CbGpPWpGaD
Fosaprepitant—Vomiting—Orlistat—obesity	0.000417	0.000831	CcSEcCtD
Fosaprepitant—Muscle spasms—Topiramate—obesity	0.000415	0.000828	CcSEcCtD
Fosaprepitant—Rash—Orlistat—obesity	0.000414	0.000825	CcSEcCtD
Fosaprepitant—Dermatitis—Orlistat—obesity	0.000413	0.000824	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCL5—obesity	0.000412	0.00117	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCKAR—obesity	0.000412	0.00117	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HRH3—obesity	0.000412	0.00117	CbGpPWpGaD
Fosaprepitant—Headache—Orlistat—obesity	0.000411	0.000819	CcSEcCtD
Fosaprepitant—Hypersensitivity—Bupropion—obesity	0.000408	0.000813	CcSEcCtD
Fosaprepitant—Vomiting—Sibutramine—obesity	0.000404	0.000805	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Topiramate—obesity	0.000401	0.000799	CcSEcCtD
Fosaprepitant—Rash—Sibutramine—obesity	0.0004	0.000798	CcSEcCtD
Fosaprepitant—Dermatitis—Sibutramine—obesity	0.0004	0.000797	CcSEcCtD
Fosaprepitant—Anaemia—Topiramate—obesity	0.000399	0.000796	CcSEcCtD
Fosaprepitant—Headache—Sibutramine—obesity	0.000398	0.000793	CcSEcCtD
Fosaprepitant—Asthenia—Bupropion—obesity	0.000397	0.000792	CcSEcCtD
Fosaprepitant—Pruritus—Bupropion—obesity	0.000392	0.000781	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRLHR—obesity	0.000391	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SH2B1—obesity	0.000391	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GH1—obesity	0.000391	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCK—obesity	0.00039	0.00111	CbGpPWpGaD
Fosaprepitant—Nausea—Orlistat—obesity	0.00039	0.000777	CcSEcCtD
Fosaprepitant—Malaise—Topiramate—obesity	0.00039	0.000777	CcSEcCtD
Fosaprepitant—Syncope—Topiramate—obesity	0.000387	0.000772	CcSEcCtD
Fosaprepitant—Palpitations—Topiramate—obesity	0.000382	0.000761	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—POMC—obesity	0.000381	0.00108	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GLP1R—obesity	0.00038	0.00108	CbGpPWpGaD
Fosaprepitant—Loss of consciousness—Topiramate—obesity	0.00038	0.000757	CcSEcCtD
Fosaprepitant—Diarrhoea—Bupropion—obesity	0.000379	0.000755	CcSEcCtD
Fosaprepitant—Nausea—Sibutramine—obesity	0.000377	0.000752	CcSEcCtD
Fosaprepitant—Cough—Topiramate—obesity	0.000377	0.000752	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CCKAR—obesity	0.000374	0.00106	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRH3—obesity	0.000374	0.00106	CbGpPWpGaD
Fosaprepitant—Hypertension—Topiramate—obesity	0.000373	0.000744	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—NPY—obesity	0.000373	0.00106	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—obesity	0.000372	0.00106	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IAPP—obesity	0.000371	0.00105	CbGpPWpGaD
Fosaprepitant—Chest pain—Topiramate—obesity	0.000368	0.000733	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—APLN—obesity	0.000367	0.00105	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PYY—obesity	0.000367	0.00105	CbGpPWpGaD
Fosaprepitant—Anxiety—Topiramate—obesity	0.000367	0.000731	CcSEcCtD
Fosaprepitant—Dizziness—Bupropion—obesity	0.000366	0.00073	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000365	0.000728	CcSEcCtD
Fosaprepitant—Discomfort—Topiramate—obesity	0.000363	0.000724	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—HTR2A—obesity	0.000363	0.00103	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—C3—obesity	0.000362	0.00103	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—obesity	0.000361	0.00103	CbGpPWpGaD
Fosaprepitant—Dry mouth—Topiramate—obesity	0.00036	0.000717	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PRKAR2B—obesity	0.00036	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CRH—obesity	0.00036	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR1B—obesity	0.00036	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—obesity	0.000358	0.00102	CbGpPWpGaD
Fosaprepitant—Oedema—Topiramate—obesity	0.000353	0.000703	CcSEcCtD
Fosaprepitant—Vomiting—Bupropion—obesity	0.000352	0.000702	CcSEcCtD
Fosaprepitant—Infection—Topiramate—obesity	0.00035	0.000698	CcSEcCtD
Fosaprepitant—Rash—Bupropion—obesity	0.000349	0.000696	CcSEcCtD
Fosaprepitant—Dermatitis—Bupropion—obesity	0.000349	0.000695	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PNLIP—obesity	0.000348	0.000991	CbGpPWpGaD
Fosaprepitant—Shock—Topiramate—obesity	0.000347	0.000692	CcSEcCtD
Fosaprepitant—Headache—Bupropion—obesity	0.000347	0.000691	CcSEcCtD
Fosaprepitant—Nervous system disorder—Topiramate—obesity	0.000346	0.000689	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—AGT—obesity	0.000344	0.00098	CbGpPWpGaD
Fosaprepitant—Skin disorder—Topiramate—obesity	0.000343	0.000683	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—NPS—obesity	0.000341	0.00097	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Topiramate—obesity	0.000341	0.00068	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SDC3—obesity	0.00034	0.000967	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NPY—obesity	0.000339	0.000964	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IAPP—obesity	0.000336	0.000958	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR2C—obesity	0.000334	0.000952	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—DRD1—obesity	0.000334	0.000952	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PMCH—obesity	0.000332	0.000945	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NPY5R—obesity	0.000332	0.000945	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HCRT—obesity	0.000332	0.000945	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NMU—obesity	0.000332	0.000945	CbGpPWpGaD
Fosaprepitant—Hypotension—Topiramate—obesity	0.00033	0.000657	CcSEcCtD
Fosaprepitant—Nausea—Bupropion—obesity	0.000329	0.000655	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CRH—obesity	0.000327	0.00093	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HTR1B—obesity	0.000327	0.00093	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB1—obesity	0.000324	0.000922	CbGpPWpGaD
Fosaprepitant—Insomnia—Topiramate—obesity	0.000319	0.000636	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NPY2R—obesity	0.000318	0.000906	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NPY1R—obesity	0.000318	0.000906	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MC4R—obesity	0.000318	0.000906	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MC3R—obesity	0.000318	0.000906	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—F2—obesity	0.000318	0.000906	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GHRL—obesity	0.000317	0.000902	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Topiramate—obesity	0.000314	0.000627	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—DRD4—obesity	0.000314	0.000895	CbGpPWpGaD
Fosaprepitant—Somnolence—Topiramate—obesity	0.000314	0.000625	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PPY—obesity	0.000312	0.000889	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Topiramate—obesity	0.00031	0.000619	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—NPS—obesity	0.00031	0.000881	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HDAC8—obesity	0.000307	0.000873	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCH—obesity	0.000307	0.000873	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GIP—obesity	0.000307	0.000873	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Topiramate—obesity	0.000307	0.000611	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Topiramate—obesity	0.000304	0.000607	CcSEcCtD
Fosaprepitant—Fatigue—Topiramate—obesity	0.000304	0.000606	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—HTR2C—obesity	0.000304	0.000864	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—DRD1—obesity	0.000304	0.000864	CbGpPWpGaD
Fosaprepitant—Constipation—Topiramate—obesity	0.000302	0.000601	CcSEcCtD
Fosaprepitant—Pain—Topiramate—obesity	0.000302	0.000601	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CNR1—obesity	0.0003	0.000854	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB1—obesity	0.000294	0.000837	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—DRD2—obesity	0.000293	0.000834	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEPR—obesity	0.000291	0.000829	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Topiramate—obesity	0.000291	0.000579	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GCG—obesity	0.00029	0.000825	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—POMC—obesity	0.00029	0.000825	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—obesity	0.000289	0.000822	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Topiramate—obesity	0.000288	0.000575	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GHRL—obesity	0.000288	0.000819	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—DRD4—obesity	0.000286	0.000813	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCL2—obesity	0.000284	0.000807	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—obesity	0.000282	0.000803	CbGpPWpGaD
Fosaprepitant—Urticaria—Topiramate—obesity	0.00028	0.000558	CcSEcCtD
Fosaprepitant—Abdominal pain—Topiramate—obesity	0.000279	0.000556	CcSEcCtD
Fosaprepitant—Body temperature increased—Topiramate—obesity	0.000279	0.000556	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CNR1—obesity	0.000273	0.000776	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—DRD2—obesity	0.000266	0.000757	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GCG—obesity	0.000263	0.000749	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—obesity	0.000262	0.000747	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB3—obesity	0.000261	0.000742	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Topiramate—obesity	0.00026	0.000518	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GAL—obesity	0.000255	0.000725	CbGpPWpGaD
Fosaprepitant—Asthenia—Topiramate—obesity	0.000253	0.000504	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—obesity	0.000252	0.000718	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—C5AR1—obesity	0.000252	0.000717	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNB3—obesity	0.00025	0.000711	CbGpPWpGaD
Fosaprepitant—Pruritus—Topiramate—obesity	0.000249	0.000497	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GNAS—obesity	0.000243	0.000692	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Topiramate—obesity	0.000241	0.000481	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—obesity	0.000238	0.000678	CbGpPWpGaD
Fosaprepitant—Dizziness—Topiramate—obesity	0.000233	0.000465	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CCL5—obesity	0.000233	0.000662	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCK—obesity	0.00023	0.000655	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKG1—obesity	0.00023	0.000655	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNB3—obesity	0.000227	0.000646	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RBP4—obesity	0.000224	0.000639	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLP1R—obesity	0.000224	0.000639	CbGpPWpGaD
Fosaprepitant—Vomiting—Topiramate—obesity	0.000224	0.000447	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—obesity	0.000223	0.000636	CbGpPWpGaD
Fosaprepitant—Rash—Topiramate—obesity	0.000222	0.000443	CcSEcCtD
Fosaprepitant—Dermatitis—Topiramate—obesity	0.000222	0.000443	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GNAS—obesity	0.000221	0.000629	CbGpPWpGaD
Fosaprepitant—Headache—Topiramate—obesity	0.000221	0.00044	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCKAR—obesity	0.000221	0.000628	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRH3—obesity	0.000221	0.000628	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKAR2B—obesity	0.000212	0.000605	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL5—obesity	0.000211	0.000601	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCD—obesity	0.00021	0.000597	CbGpPWpGaD
Fosaprepitant—Nausea—Topiramate—obesity	0.000209	0.000418	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NCF2—obesity	0.000205	0.000584	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR2A—obesity	0.000205	0.000584	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—C3—obesity	0.000205	0.000583	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NPY—obesity	0.0002	0.000569	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOC3—obesity	0.000199	0.000566	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IAPP—obesity	0.000199	0.000566	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGT—obesity	0.000195	0.000554	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HTR1B—obesity	0.000193	0.000549	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CRH—obesity	0.000193	0.000549	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SDC1—obesity	0.000191	0.000543	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCD—obesity	0.00019	0.000542	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKR1C3—obesity	0.000188	0.000534	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HTR2A—obesity	0.000186	0.00053	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—C3—obesity	0.000186	0.000529	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NPS—obesity	0.000183	0.000521	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—F2—obesity	0.00018	0.000512	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCB—obesity	0.00018	0.000512	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HTR2C—obesity	0.000179	0.000511	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DRD1—obesity	0.000179	0.000511	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGT—obesity	0.000177	0.000503	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NTRK2—obesity	0.000174	0.000497	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB1—obesity	0.000174	0.000494	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—obesity	0.000172	0.00049	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHRL—obesity	0.00017	0.000484	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PARP1—obesity	0.00017	0.000484	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DRD4—obesity	0.000169	0.00048	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—POMC—obesity	0.000164	0.000466	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—F2—obesity	0.000163	0.000465	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCB—obesity	0.000163	0.000465	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CNR1—obesity	0.000161	0.000458	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TCF7L2—obesity	0.000158	0.00045	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT2—obesity	0.000157	0.000448	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DRD2—obesity	0.000157	0.000447	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—obesity	0.000156	0.000445	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GCG—obesity	0.000156	0.000443	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTPN1—obesity	0.000156	0.000443	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CD—obesity	0.000151	0.000431	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—POMC—obesity	0.000149	0.000423	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRL—obesity	0.000148	0.000422	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STK11—obesity	0.000146	0.000416	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL2—obesity	0.000146	0.000414	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLG—obesity	0.000145	0.000412	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RHOA—obesity	0.000144	0.000411	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT2—obesity	0.000143	0.000407	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3R1—obesity	0.000143	0.000407	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FOXO3—obesity	0.000141	0.000402	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—obesity	0.000141	0.000401	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SOCS1—obesity	0.000139	0.000395	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CD—obesity	0.000137	0.000391	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SOCS3—obesity	0.000137	0.00039	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNB3—obesity	0.000134	0.000382	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—TYK2—obesity	0.000132	0.000376	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CB—obesity	0.000132	0.000375	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF2—obesity	0.000132	0.000375	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RHOA—obesity	0.000131	0.000373	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNAS—obesity	0.000131	0.000371	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3R1—obesity	0.00013	0.000369	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOB—obesity	0.000128	0.000364	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL5—obesity	0.000125	0.000355	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LPL—obesity	0.000122	0.000347	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FOXO1—obesity	0.000121	0.000345	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RPS6KB1—obesity	0.000121	0.000344	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CB—obesity	0.00012	0.000341	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCD—obesity	0.000112	0.00032	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HTR2A—obesity	0.00011	0.000313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—C3—obesity	0.00011	0.000313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS2—obesity	0.000105	0.000298	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGT—obesity	0.000104	0.000297	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOE—obesity	0.000102	0.000291	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEP—obesity	0.000102	0.000291	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CAV1—obesity	0.000101	0.000288	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA1—obesity	0.000101	0.000288	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ESR1—obesity	9.77e-05	0.000278	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—F2—obesity	9.65e-05	0.000275	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCB—obesity	9.65e-05	0.000275	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BAD—obesity	9.53e-05	0.000271	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—obesity	9.23e-05	0.000263	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS1—obesity	9.13e-05	0.00026	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—POMC—obesity	8.79e-05	0.00025	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INS—obesity	8.74e-05	0.000249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL2—obesity	8.6e-05	0.000245	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—obesity	8.45e-05	0.000241	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT2—obesity	8.45e-05	0.00024	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CD—obesity	8.12e-05	0.000231	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—obesity	8.04e-05	0.000229	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—obesity	8.03e-05	0.000228	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TYK2—obesity	7.81e-05	0.000222	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RHOA—obesity	7.74e-05	0.00022	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3R1—obesity	7.66e-05	0.000218	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—obesity	7.66e-05	0.000218	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—obesity	7.3e-05	0.000208	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MTOR—obesity	7.07e-05	0.000201	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CB—obesity	7.07e-05	0.000201	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—obesity	6.57e-05	0.000187	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—obesity	6.46e-05	0.000184	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—obesity	6.15e-05	0.000175	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK8—obesity	5.98e-05	0.00017	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—obesity	5.96e-05	0.00017	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—obesity	5.47e-05	0.000156	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—obesity	5.08e-05	0.000145	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—obesity	5.07e-05	0.000144	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—obesity	4.31e-05	0.000123	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—obesity	3.82e-05	0.000109	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—obesity	3.52e-05	0.0001	CbGpPWpGaD
